- Home
- EQX vs GERN Comparison
EQX vs GERN Comparison
Compare EQX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- GERN
- Stock Information
- Founded
- EQX 2007
- GERN 1990
- Country
- EQX Canada
- GERN United States
- Employees
- EQX N/A
- GERN N/A
- Industry
- EQX Precious Metals
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- GERN Health Care
- Exchange
- EQX Nasdaq
- GERN Nasdaq
- Market Cap
- EQX 2.3B
- GERN 2.5B
- IPO Year
- EQX N/A
- GERN 1996
- Fundamental
- Price
- EQX $5.84
- GERN $2.89
- Analyst Decision
- EQX
- GERN Strong Buy
- Analyst Count
- EQX 0
- GERN 10
- Target Price
- EQX N/A
- GERN $7.15
- AVG Volume (30 Days)
- EQX 5.5M
- GERN 14.8M
- Earning Date
- EQX 02-21-2025
- GERN 02-26-2025
- Dividend Yield
- EQX N/A
- GERN N/A
- EPS Growth
- EQX 302.88
- GERN N/A
- EPS
- EQX 0.60
- GERN N/A
- Revenue
- EQX $1,236,929,000.00
- GERN $29,480,000.00
- Revenue This Year
- EQX $45.56
- GERN $31,478.06
- Revenue Next Year
- EQX $57.70
- GERN $290.89
- P/E Ratio
- EQX $10.88
- GERN N/A
- Revenue Growth
- EQX 17.84
- GERN 9199.68
- 52 Week Low
- EQX $3.95
- GERN $1.64
- 52 Week High
- EQX $6.50
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- EQX 56.46
- GERN 25.84
- Support Level
- EQX $5.79
- GERN $2.80
- Resistance Level
- EQX $6.15
- GERN $3.68
- Average True Range (ATR)
- EQX 0.21
- GERN 0.18
- MACD
- EQX 0.08
- GERN -0.04
- Stochastic Oscillator
- EQX 73.87
- GERN 10.23
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing pipeline of growth projects.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.